PharmaJet’s Tropis system is now the exclusive intradermal delivery system for two authorized novel COVID-19 vaccines. They include: The world’s first plasmid DNA COVID-19 vaccine for administration in humans from Zydus...
PharmaJet named Marie Mazur, PharmD, chairwoman of the board, replacing Ron Lowy, who had chaired the board since 2011. “Marie’s experience and leadership will be of great benefit for our company as we are accelerating...
PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...
Closely-held PharmaJet will present results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods at the World Vaccine Congress 2023 on April 5...
PharmaJet partner, Gennova Biopharmaceuticals, filed data for its mRNA-based Omicron specific COVID-19 booster shot for emergency use authorization (EUA) to the office of the Drug Controller General of India. The...
PharmaJet partner, Immunomic Therapeutics, received FDA fast track designation for a clinical study of its plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin...
Closely-held PharmaJet received an $800,000-plus direct to Phase 2 grant from the NIH to evaluate the immunogenicity of intradermal administration of human papilloma virus (HPV) vaccine using the company’s Tropis...
Closely-held PharmaJet received a multi-year, $1.5-million grant from the United States Agency for International Development (USAID) to evaluate the impact of intradermal vaccine administration using the company’s...
PharmaJet partner, Scancell, will include PharmaJet’s needle-free delivery system in a Phase 2 clinical study of a vaccine for treatment of patients with advanced melanoma. Scancell’s immunotherapy platform uses the...
A Phase 3 clinical study sponsored by PharmaJet’s partner, Zydus Lifesciences, featuring ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans and delivered by the PharmaJet Tropis Intradermal needle...